Yale Cancer Center NCTN LAPS

项目摘要 耶鲁癌症中心在查尔斯博士的领导下继续参与NCTN Fuchs不仅包括NCTN试验的强大和承诺的可靠历史， 在SWOG和其他团体的试验工作中发挥强有力的领导作用。YCC仍然致力于 优先考虑所有YCC临床中心的NCTN试验， 在我们目前的U10奖项中开发的估计。在本次提交的文件中， YCC领导层的职责是：1）继续优先考虑NCTN试验，并将YCC发展为 主要贡献者的群体试验与我们的护理中心的额外贡献; 2）促进和 鼓励YCC教师承担SWOG和其他NCTN团体的领导角色， 支持他们的时间和努力，并奖励这些活动;以及3）利用我们的NCTN 协调委员会（NCC）作为一个桥梁，使耶鲁大学翻译科学组 作为我们的研究者发起的试点试验的结果，多中心活动变得很有希望 和随机问题。除了Fuchs博士的领导努力外，其他关键SWOG 领导人包括罗伊·赫布斯特博士、丹尼尔·彼得里拉克博士和拉霍斯·普斯泰博士。Peter Glazer博士，Roy 除了Barbara博士，德克尔和Alessandro Rumann将领导我们在NRG组的工作 Burtness将继续领导我们在ECOG-ACRIN小组的工作。我们认为 YCC的科学和翻译工作有很大的潜力纳入NCTN 程序.继续致力于早期药物开发、EGFR耐药、PD-1信号传导， 化学生物学，以及通过YCC的科学计划进行信号转导的新目标 很有可能转化为群体试验。此外，随着Smilow的扩张， 癌症医院护理中心，我们证明了一个更大的机会，使NCTN试验， 康涅狄格州的病人人数越来越多。UG 1将帮助我们 发展适当的领导和基础设施，以支持NCTN集团的关键工作 在权责发生制和程序开发方面。

Project Summary Yale Cancer Center's continuing participation in the NCTN under the leadership of Dr. Charles Fuchs includes not only a solid history of strong and committed accrual to NCTN trials, but strong leadership in the trials efforts at SWOG and other groups. YCC remains committed to prioritizing NCTN trials at all the YCC clinical centers and demonstrates annual accrual beyond estimates developed in our current U10 award. For this current submission, the vision of the YCC leadership is to: 1) continue to prioritize NCTN trials for accrual and develop YCC as a major contributor to group trials with additional contribution of our Care Centers; 2) facilitate and encourage YCC faculty to assume leadership roles in SWOG and other NCTN groups by supporting their time and effort and rewarding these activities; and 3) leverage our NCTN Coordinating Committee (NCC) as a bridge to bring Yale translational science to group activities as the results of our investigator initiated pilot trials become promising for multi-center and randomized questions. In addition to the leadership efforts of Dr. Fuchs, other key SWOG leaders include Drs. Roy Herbst, Daniel Petrylak and Lajos Pusztai. Drs. Peter Glazer, Roy Decker and Alessandro Santin will lead our efforts in the NRG group in addition to Dr. Barbara Burtness who will continue to lead our efforts in the ECOG-ACRIN group. We believe that the science and translational work at YCC has strong potential for incorporation into NCTN programs. Continued work on early phase drug development, EGFR resistance, PD-1 signaling, chemical biology, and new targets in signal transduction through the scientific programs of YCC have strong potential for translation into group trials. Furthermore, with expansion of the Smilow Cancer Hospital Care Centers, we demonstrated a greater opportunity to bring NCTN trials to the greater patient population across the state of Connecticut. This UG1 grant will assist us in developing the appropriate leadership and infrastructure for support of key NCTN group efforts in both accrual and program development.